In using the prediction tools, you agree that neither MSKCC nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to your use of any information presented in the prediction tools. You are hereby advised to consult with a physician or other professional healthcare provider prior to making any decisions, or undertaking any actions or not undertaking any actions related to any healthcare problem or issue you might have at any time, now or in the future. MSKCC does not record specific prediction tool user information and does not contact users of the prediction tools. The activities and products of MSKCC and its developers and agents (collectively MSKCC) are not endorsed by our past, present, or future employers. MSKCC does not endorse or claim validity for the prediction tools found on the MSKCC Web site. Use of the prediction tools does not create an express or implied physician-patient relationship. After radiation therapy, metastasis developed in 45.9 with a PSADT shorter than 6 months, but in only 8.3 with a PSADT longer than 6 months. Health related information changes frequently and therefore information contained in the prediction tools may be outdated, incomplete or incorrect. MSKCC does not assume any risk whatsoever for your use of the prediction tools or the information contained herein. MSKCC makes no warranties, nor express or implied representations whatsoever, regarding the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced in the prediction tools.

Questions should be addressed to your own physician or other healthcare provider. The median overall survival time was 21.37 months for these. Users of the prediction tools should not rely on information provided by the prediction tools for their own health problems. The group of patients who had PSA-R < 50, had significantly lower survival rates (p 0.049). The prediction tools are not to be used as a substitute for medical advice, diagnosis, or treatment of any health condition or problem. The prediction tools, also known as prognostic nomograms, located on the MSKCC Web site are for general health information only. Find a Researcher Programs & Centers Postdoctoral Positions Research Topics.Gerstner Sloan Kettering Graduate School of Biomedical Sciences.Find a Doctor Refer a Patient Newsletter Sign Up Clinical Trials.Anesthesiology & Critical Care Medicine.Find a Doctor Make an Appointment Visitor Information FAQ The PSA doubling time Whether the recurrence occurred within three years or after three years A recurrence that occurs within three years reduces survival rates by anywhere from 15 to 20and even more, if the doubling time is short.Find a Doctor Make an Appointment Visitor Information MyMSK.

Psa doubling time survival rate